A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Trial Profile

A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2016 The company has initiated dosing in this trial and top-line data are expected in 2017, according to a Tracon Pharmaceuticals media release.
    • 18 Feb 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019 as reported by ClinicalTrials.gov.
    • 18 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top